Novel fusion of GLP-1 with a domain antibody to serum albumin prolongs protection against myocardial ischemia/reperfusion injury in the rat
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Novel fusion of GLP-1 with a domain antibody to serum albumin prolongs protection against myocardial ischemia/reperfusion injury in the rat
Authors
Keywords
Glucagon-like peptide-1 (GLP-1), Exendin-4, Anti-albumin-binding domain antibody, Rat, Cardioprotection
Journal
Cardiovascular Diabetology
Volume 12, Issue 1, Pages 148
Publisher
Springer Nature
Online
2013-10-14
DOI
10.1186/1475-2840-12-148
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cyclic AMP-mediated pleiotropic effects of glucagon-like peptide-1 receptor activation. Focus on “Exendin-4 attenuates high glucose-induced cardiomyocyte apoptosis via inhibition of endoplasmic reticulum stress and activation of SERCA2a”
- (2013) Yumei Ye et al. AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY
- Glucagon-like peptide-1 preserves coronary microvascular endothelial function after cardiac arrest and resuscitation: potential antioxidant effects
- (2012) Betsy B. Dokken et al. AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY
- Exenatide Reduces Final Infarct Size in Patients With ST-Segment–Elevation Myocardial Infarction and Short-Duration of Ischemia
- (2012) Jacob Lønborg et al. Circulation-Cardiovascular Interventions
- Antiapoptotic Actions of Exendin-4 against Hypoxia and Cytokines Are Augmented by CREB
- (2012) Kalpana Velmurugan et al. ENDOCRINOLOGY
- Myocardial Protection Against Ischemia-Reperfusion Injury by GLP-1: Molecular Mechanisms
- (2012) Yochai Birnbaum et al. Metabolic Syndrome and Related Disorders
- Péptido similar al glucagón tipo 1 y supervivencia de la célula cardiaca
- (2012) Susana Ravassa et al. Endocrinologia y Nutricion
- Glucagon-like peptide-1 enhances cardiac L-type Ca2+ currents via activation of the cAMP-dependent protein kinase A pathway
- (2011) Yong-Fu Xiao et al. Cardiovascular Diabetology
- Glucagon-like Peptide-1 (GLP-1), Immediately Prior to Reperfusion, Decreases Neutrophil Activation and Reduces Myocardial Infarct Size in Rodents
- (2011) B. B. Dokken et al. HORMONE AND METABOLIC RESEARCH
- DPP4 deficiency preserves cardiac function via GLP-1 signaling in rats subjected to myocardial ischemia/reperfusion
- (2011) Hui-Chun Ku et al. NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY
- Albiglutide, a Long Lasting Glucagon-Like Peptide-1 Analog, Protects the Rat Heart against Ischemia/Reperfusion Injury: Evidence for Improving Cardiac Metabolic Efficiency
- (2011) Weike Bao et al. PLoS One
- Glucagon-like peptide-1 and the exenatide analogue AC3174 improve cardiac function, cardiac remodeling, and survival in rats with chronic heart failure
- (2010) Que Liu et al. Cardiovascular Diabetology
- Pharmacokinetics and Pharmacodynamics of Exenatide Extended-Release After Single and Multiple Dosing
- (2010) Mark Fineman et al. CLINICAL PHARMACOKINETICS
- Anti-serum albumin domain antibodies in the development of highly potent, efficacious and long-acting interferon
- (2010) A. Walker et al. PROTEIN ENGINEERING DESIGN & SELECTION
- Emerging cardiovascular actions of the incretin hormone glucagon-like peptide-1: potential therapeutic benefits beyond glycaemic control?
- (2009) David J Grieve et al. BRITISH JOURNAL OF PHARMACOLOGY
- Potential of Albiglutide, a Long-Acting GLP-1 Receptor Agonist, in Type 2 Diabetes: A randomized controlled trial exploring weekly, biweekly, and monthly dosing
- (2009) J. Rosenstock et al. DIABETES CARE
- Exenatide Reduces Infarct Size and Improves Cardiac Function in a Porcine Model of Ischemia and Reperfusion Injury
- (2009) Leo Timmers et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)
- (2009) John B Buse et al. LANCET
- Cardioprotective and Vasodilatory Actions of Glucagon-Like Peptide 1 Receptor Are Mediated Through Both Glucagon-Like Peptide 1 Receptor–Dependent and –Independent Pathways
- (2008) Kiwon Ban et al. CIRCULATION
- New treatments in type 2 diabetes: a focus on the incretin-based therapies
- (2008) Anthony H. Barnett CLINICAL ENDOCRINOLOGY
- In Vivo Activation of Peroxisome Proliferator-Activated Receptor- Protects the Heart from Ischemia/Reperfusion Injury in Zucker Fatty Rats
- (2008) T.-L. Yue et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Anti-serum albumin domain antibodies for extending the half-lives of short lived drugs
- (2008) L. J. Holt et al. PROTEIN ENGINEERING DESIGN & SELECTION
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now